Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Oct 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms FARAONIC
- Sponsors Bayer
- 10 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2019 Planned End Date changed from 30 Aug 2021 to 30 Oct 2021.
- 12 Jul 2019 Planned primary completion date changed from 28 Jun 2021 to 31 Jul 2021.